Hillhouse Medical Group

Hillhouse Medical Group PLLC is a Houston, Texas-based medical practice and clinical research organization specializing in nephrology and internal medicine. Led by Dr. Michael Z. Yu, the group provides comprehensive patient care while actively participating in translational medicine and drug discovery. In collaboration with Singularity Therapeutics, Hillhouse Medical Group has co-developed ST-301, a novel, highly selective small molecule Toll-like receptor 7 (TLR7) inhibitor, and ST-303, a dual TLR7/8 inhibitor. Preclinical studies of these candidates have demonstrated robust efficacy in delaying the onset and progression of lupus nephritis and improving survival in murine models of systemic lupus erythematosus (SLE).